scholarly journals Machine‐learning‐based Alzheimer's disease dementia score using structural MRI neurodegeneration patterns: Independent validation on ADNI, AIBL, OASIS and MIRIAD

2020 ◽  
Vol 16 (S5) ◽  
Author(s):  
Karteek Popuri ◽  
Da Ma ◽  
Lei Wang ◽  
Mirza Faisal Beg
Keyword(s):  
Machine Learning ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Structural Mri ◽  
Independent Validation ◽  
Alzheimer’S Disease Dementia

scholarly journals Machine learning methods for predicting progression from mild cognitive impairment to Alzheimer’s disease dementia: a systematic review

2021 ◽  
Vol 13 (1) ◽  
Author(s):  
Sergio Grueso ◽  
Raquel Viejo-Sobera
Keyword(s):  
Machine Learning ◽  
Systematic Review ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Early Detection ◽  
Neurocognitive Disorders ◽  
Support Vector ◽  
Alzheimer’S Disease Dementia

Abstract Background An increase in lifespan in our society is a double-edged sword that entails a growing number of patients with neurocognitive disorders, Alzheimer’s disease being the most prevalent. Advances in medical imaging and computational power enable new methods for the early detection of neurocognitive disorders with the goal of preventing or reducing cognitive decline. Computer-aided image analysis and early detection of changes in cognition is a promising approach for patients with mild cognitive impairment, sometimes a prodromal stage of Alzheimer’s disease dementia. Methods We conducted a systematic review following PRISMA guidelines of studies where machine learning was applied to neuroimaging data in order to predict whether patients with mild cognitive impairment might develop Alzheimer’s disease dementia or remain stable. After removing duplicates, we screened 452 studies and selected 116 for qualitative analysis. Results Most studies used magnetic resonance image (MRI) and positron emission tomography (PET) data but also magnetoencephalography. The datasets were mainly extracted from the Alzheimer’s disease neuroimaging initiative (ADNI) database with some exceptions. Regarding the algorithms used, the most common was support vector machine with a mean accuracy of 75.4%, but convolutional neural networks achieved a higher mean accuracy of 78.5%. Studies combining MRI and PET achieved overall better classification accuracy than studies that only used one neuroimaging technique. In general, the more complex models such as those based on deep learning, combined with multimodal and multidimensional data (neuroimaging, clinical, cognitive, genetic, and behavioral) achieved the best performance. Conclusions Although the performance of the different methods still has room for improvement, the results are promising and this methodology has a great potential as a support tool for clinicians and healthcare professionals.

Neuroimage Classification for Early Diagnosis of Alzheimer’s Disease

2012 ◽  
pp. 336-350
Author(s):  
Yong Fan ◽  
Christos Davatzikos
Keyword(s):  
Machine Learning ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Psychiatric Disorders ◽  
General Framework ◽  
Disease Onset ◽  
Structural Mri ◽  
Early Prediction ◽  
Psychometric Assessment ◽  
Combining Information

Diagnostic criteria for neurological and psychiatric disorders are typically based on clinical and psychometric assessment, which might not be effective for early detection of the disease onset. For brain disorders such as Alzheimer’s Disease (AD), neuroimaging can potentially play an important role in the development of imaging-based biomarkers. Following voxel-wise univariate neuroimage analysis methods, machine learning and pattern recognition based neuroimage analysis techniques have been increasingly adopted in neuroimaging studies of neurological and psychiatric disorders, aiming to provide tools that classify individuals, based on their neuroimaging scans, rather than detect statistical group difference. The machine learning based methods, optimally combining information of multiple measures derived from images, have demonstrated promising performance in diagnosis of AD and early prediction of conversion of Mild Cognitive Impairment (MCI) individuals. This chapter introduces the general framework of such techniques with a focus on structural MRI analyses and their applications to studies of AD.

scholarly journals A machine learning-based holistic approach for diagnoses within the Alzheimer's disease spectrum

2020 ◽  
Author(s):  
Noemi Massetti ◽  
Alberto Granzotto ◽  
Manuela Bomba ◽  
Stefano Delli Pizzi ◽  
Alessandra Mosca ◽  
...  
Keyword(s):  
Machine Learning ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Healthy Aging ◽  
Holistic Approach ◽  
Structural Mri ◽  
Relative Contribution ◽  
Disease Spectrum ◽  
Organ Specific ◽  
The Central Nervous System

Alzheimer's disease (AD) is a neurodegenerative condition driven by a multifactorial etiology. We employed a machine learning (ML) based algorithm and the wealth of information offered by the Alzheimer's Disease Neuroimaging Initiative (ADNI) database to investigate the relative contribution of clinically relevant factors for identifying subjects affected by Mild Cognitive Impairment (MCI), a transitional status between healthy aging and dementia. Our ML-based Random Forest (RF) algorithm did not help predict clinical outcomes and the AD conversion of MCI subjects. On the other hand, non-converting (ncMCI) subjects were correctly classified and predicted. Two neuropsychological tests, the FAQ and ADAS13, were the most relevant features used for the classification and prediction of younger, under 70, ncMCI subjects. Structural MRI data combined with systemic parameters and the cardiovascular status were instead the most critical factors for the classification of over 70 ncMCI subjects. Our results support the notion that AD is not an organ-specific condition and results from pathological processes inside and outside the Central Nervous System.

scholarly journals Atrophy subtypes in prodromal Alzheimer’s disease are associated with cognitive decline

Brain ◽  
2018 ◽  
Vol 141 (12) ◽  
pp. 3443-3456 ◽  
Author(s):  
Mara ten Kate ◽  
Ellen Dicks ◽  
Pieter Jelle Visser ◽  
Wiesje M van der Flier ◽  
Charlotte E Teunissen ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Decline ◽  
External Validation ◽  
Structural Mri ◽  
Vascular Lesions ◽  
Cortical Atrophy ◽  
Executive Attention ◽  
Prodromal Alzheimer’S Disease ◽  
Alzheimer’S Disease Dementia

Abstract Alzheimer’s disease is a heterogeneous disorder. Understanding the biological basis for this heterogeneity is key for developing personalized medicine. We identified atrophy subtypes in Alzheimer’s disease dementia and tested whether these subtypes are already present in prodromal Alzheimer’s disease and could explain interindividual differences in cognitive decline. First we retrospectively identified atrophy subtypes from structural MRI with a data-driven cluster analysis in three datasets of patients with Alzheimer’s disease dementia: discovery data (dataset 1: n = 299, age = 67 ± 8, 50% female), and two independent external validation datasets (dataset 2: n = 181, age = 66 ± 7, 52% female; dataset 3: n = 227, age = 74 ± 8, 44% female). Subtypes were compared on clinical, cognitive and biological characteristics. Next, we classified prodromal Alzheimer’s disease participants (n = 603, age = 72 ± 8, 43% female) according to the best matching subtype to their atrophy pattern, and we tested whether subtypes showed cognitive decline in specific domains. In all Alzheimer’s disease dementia datasets we consistently identified four atrophy subtypes: (i) medial-temporal predominant atrophy with worst memory and language function, older age, lowest CSF tau levels and highest amount of vascular lesions; (ii) parieto-occipital atrophy with poor executive/attention and visuospatial functioning and high CSF tau; (iii) mild atrophy with best cognitive performance, young age, but highest CSF tau levels; and (iv) diffuse cortical atrophy with intermediate clinical, cognitive and biological features. Prodromal Alzheimer’s disease participants classified into one of these subtypes showed similar subtype characteristics at baseline as Alzheimer’s disease dementia subtypes. Compared across subtypes in prodromal Alzheimer’s disease, the medial-temporal subtype showed fastest decline in memory and language over time; the parieto-occipital subtype declined fastest on executive/attention domain; the diffuse subtype in visuospatial functioning; and the mild subtype showed intermediate decline in all domains. Robust atrophy subtypes exist in Alzheimer’s disease with distinct clinical and biological disease expression. Here we observe that these subtypes can already be detected in prodromal Alzheimer’s disease, and that these may inform on expected trajectories of cognitive decline.

scholarly journals Diagnosis and Prognosis of Alzheimer’s Disease Using Brain Morphometry and White Matter Connectomes

2018 ◽  
Author(s):  
Yun Wang ◽  
Chenxiao Xu ◽  
Ji-Hwan Park ◽  
Seonjoo Lee ◽  
Yaakov Stern ◽  
...  
Keyword(s):  
Machine Learning ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
White Matter ◽  
Diffusion Mri ◽  
Structural Mri ◽  
List Type ◽  
Csf Biomarker ◽  
Multimodal Mri ◽  
And Diffusion

ABSTRACTAccurate, reliable prediction of risk for Alzheimer’s disease (AD) is essential for early, disease-modifying therapeutics. Multimodal MRI, such as structural and diffusion MRI, is likely to contain complementary information of neurodegenerative processes in AD. Here we tested the utility of the multimodal MRI (T1-weighted structure and diffusion MRI), combined with high-throughput brain phenotyping—morphometry and structural connectomics—and machine learning, as a diagnostic tool for AD. We used, firstly, a clinical cohort at a dementia clinic (National Health Insurance Service-Ilsan Hospital [NHIS-IH]; N=211; 110 AD, 64 mild cognitive impairment [MCI], and 37 cognitively normal with subjective memory complaints [SMC]) to test the diagnostic models; and, secondly, Alzheimer’s Disease Neuroimaging Initiative (ADNI)-2 to test the generalizability. Our machine learning models trained on the morphometric and connectome estimates (number of features=34,646) showed optimal classification accuracy (AD/SMC: 97% accuracy, MCI/SMC: 83% accuracy; AD/MCI: 97% accuracy) in NHIS-IH cohort, outperforming a benchmark model (FLAIR-based white matter hyperintensity volumes). In ADNI-2 data, the combined connectome and morphometry model showed similar or superior accuracies (AD/HC: 96%; MCI/HC: 70%; AD/MCI: 75% accuracy) compared with the CSF biomarker model (t-tau, p-tau, and Amyloid β, and ratios). In predicting MCI to AD progression in a smaller cohort of ADNI-2 (n=60), the morphometry model showed similar performance with 69% accuracy compared with CSF biomarker model with 70% accuracy. Our comparison of classifiers trained on structural MRI, diffusion MRI, FLAIR, and CSF biomarkers show the promising utility of the white matter structural connectomes in classifying AD and MCI in addition to the widely used structural MRI-based morphometry, when combined with machine learning.HighlightsWe showed the utility of multimodal MRI, combining morphometry and white matter connectomes, to classify the diagnosis of AD and MCI using machine learning.In predicting the progression from MCI to AD, the morphometry model showed the best performance.Two independent clinical datasets were used in this study: one for model building, the other for generalizability testing.

Sign in / Sign up

Export Citation Format

Share Document